NL-OMON24822
Not yet recruiting
Not Applicable
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysispatients
Sint Lucas Andreas ziekenhuis0 sites114 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sint Lucas Andreas ziekenhuis
- Enrollment
- 114
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Hemodialysis patients older than 18 years
- •2\. Secundary hyperparathyroidism
Exclusion Criteria
- •1\. Severe hypercalcemia
- •2\. Severe liver failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidismNL-OMON24070Het Sint Lucas Andreas ziekenhuis114
Active, not recruiting
Not Applicable
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2007-006645-41-NLSint Lucas Andreas Hospital
Recruiting
Phase 4
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149NL-OMON31628Sint Lucas Andreas Ziekenhuis114
Terminated
Phase 4
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13
Recruiting
Early Phase 1
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitisChronic PancreatitisNCT05664880Cedars-Sinai Medical Center24